(Q43282343)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

18 November 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study (English)

1 reference

18 November 2017

1 reference

3

Björn Dahlöf

0 references

author name string

Takahisa Sawada

1

1 reference

18 November 2017

Hiroyuki Yamada

2

1 reference

18 November 2017

Hiroaki Matsubara

4

1 reference

18 November 2017

KYOTO HEART Study Group

5

1 reference

18 November 2017

publication date

31 August 2009

1 reference

18 November 2017

published in

European Heart Journal

1 reference

18 November 2017

volume

30

1 reference

18 November 2017

issue

20

1 reference

18 November 2017

page(s)

2461-2469

1 reference

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

18 November 2017

cites work

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1016/S0140-6736(07)60669-2

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Angiotensin receptor blockers: how important is selectivity?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Angiotensin-Converting Enzyme Inhibitors

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Sum and substance in the Jikei Heart Study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluati

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1093/EURHEARTJ/EHP363

Identifiers

DOI

10.1093/EURHEARTJ/EHP363

1 reference

18 November 2017

1 reference